Dr. Anil S. Jina presenting at the DEBRA Ireland family day and some of the families enjoying the butterfly garden.

Shire, the global specialty biopharmaceutical company, recently announced its acquisition of Lotus Tissue Repair and their recombinant collagen VII protein replacement therapy which is in development for the treatment of DEB. Following this recent announcement, Dr. Anil S. Jina, Vice President and Head of Global Medical Affairs at Shire, attended DEBRA Ireland’s family day on May 12th.

Read More
DEBRA International

The value of DEBRA International is never clearer than at the EB research conference, which it organises every three years. The 2012 conference was held in November in Marbella, Spain, and brought together almost 100 of the world’s top EB researchers, and a number of patient representatives.

Read More
Shire

In big news for the EB community, it was announced in January 2013 that the global pharmaceutical company, Shire, has signed an agreement to acquire Lotus Tissue Repair, the biotech company currently developing a protein replacement therapy for dystrophic EB (DEB).

Read More

We are so grateful to each and every one of our supporters who sold raffle tickets for us in 2012. Because of your help and support, we raised valuable funds which are going to our Patient Support Services – to continue existing services and to help us expand on them.

Read More